Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent Inc.

The latest announcement is out from Nuvalent ( ($NUVL) ). On November 17, 2025, Nuvalent announced positive topline pivotal data for neladalkib in ...

Nuvalent Announces Positive Data for ALKOVE-1 Trial

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Nuvalent, with a price target of $112.00. The company’s shares cl...

Barclays Keeps Their Buy Rating on Nuvalent (NUVL)

Nuvalent, Inc. Class A (($NUVL)) announced an update on their ongoing clinical study. Nuvalent, Inc. is conducting a study titled ‘A Phase 1a/1b St...

Nuvalent’s NVL-330 Study: A Potential Game-Changer for HER2-Altered NSCLC

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

Market Cap	$6.70B	P/E Ratio	N/A
52W High	$112.88	52W Low	$55.54
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	87.8%
Overall Score	65	Value Score	40
Quality Score	--	Technical Score	90

EPS Current Est	$-5.69	EPS Next Est	$-6.17
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NUVL	$105.88	-1.97%	1.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NUVL	$105.88	-2.0%	1.22M
3
4
5
6

NUVL

NUVL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Nuvalent Inc. Data in Excel

Get Nuvalent Inc. Data in Excel